NCT02769078View on ClinicalTrials.gov

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

CompletedOBSERVATIONAL
Enrollment

14,201

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Atrial Fibrillation
Interventions
DRUG

dabigatran

DRUG

rivaroxaban

DRUG

apixaban

DRUG

warfarin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02769078 - Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S | Biotech Hunter | Biotech Hunter